Smoking during radiotherapy for head and neck cancer and acute mucosal reaction

Szeszko, Beata; Osowiecka, Karolina; Rucińska, Monika; Wasilewska-Teśluk, Ewa; Glinski, Krzysztof; Kępka, Lucyna

doi:10.1016/j.rpor.2015.04.001

Cited by 14 publications

(14 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Epidemiological studies have revealed an association between exposure to carcinogens (such as tobacco and alcohol), infection by oncogenic human papillomavirus types 16 and 18 (HPV16 and HPV18, respectively) and the increased risk of HNSCC development (3). Currently, the treatment of HNSCC consists of surgery followed by postoperative chemo-and/or radiotherapy (4,5). However, the 5-year mortality rate of patients with HNSCC has not improved, despite the advanced treatment methods (6).…”

Section: Introductionmentioning

confidence: 99%

hTERT C250T promoter mutation and telomere length as a molecular markers of cancer progression in patients with head and neck cancer

Barczak

Suchorska

Sobecka

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

Squamous cell carcinoma of the head and neck (HNSCC) is the sixth leading cause of cancer worldwide, representing over half a million incidents every year. Cancer cells, including HNSCC, are characterized by increased telomerase activity. This enzymatic complex is active in ~90% of all cancer types and is responsible for the lengthening of telomeres. Highly recurrent point mutations in the human telomerase reverse transcriptase (hTERT) promoter have recently been reported in a number of human neoplasms. The aim of the present study was to analyze the prevalence of the hTERT promoter C250T mutation and telomere length in the blood leukocytes of 61 patients with HNSCC and 49 healthy individuals. Quantitative polymerase chain reaction identified the hTERT promoter mutation in 36% of patients with HNSCC. To the best of our knowledge this is first report indicating the presence of shorter telomeres in early stage tumors. In addition, the results suggest that the C250T hTERT promoter mutation and telomere length assessment may serve as important molecular markers of HNSCC progression.

show abstract

Section: Introductionmentioning

confidence: 99%

hTERT C250T promoter mutation and telomere length as a molecular markers of cancer progression in patients with head and neck cancer

Barczak

Suchorska

Sobecka

et al. 2017

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…postoperative complications, are unfavorable in survivors undergoing radiation, chemotherapy, and surgical treatments (Clark et al, 2007;Duffy et al, 2013;Fortin, Wang, & Vigneault, 2009;Peppone et al, 2011;Szeszko et al, 2015). In addition, continued smoking can worsen the late and long-term sequelae of cancer treatment, which commonly include hypertension and cardiac disease (Leach et al, 2015).…”

mentioning

confidence: 99%

Smoking Prevalence and Management Among Cancer Survivors

Ehrenzeller¹,

Mayer²,

Goldstein³

2018

ONF

View full text Add to dashboard Cite

show abstract

“…Some studies have reported a negative impact of continued smoking on treatment tolerance and outcomes in patients with head and neck cancer 65,66 . However, the data from other studies do not confirm this hypothesis 67 .…”

Section: Prognostic Factors In Hpv-opcmentioning

confidence: 80%

Has the time come for de-escalation in the management of oropharyngeal carcinoma?

Durkova¹,

Boldis²,

Kovacova

2019

BIOMED PAP

View full text Add to dashboard Cite

Over the course of the last two decades, there has been a decrease in the incidence of head and neck cancers thanks to a decreasing prevalence of smoking. However, a new risk factor has been coming to the fore: human papillomavirus infection (HPV). HPV-positive oropharyngeal squamous cell carcinoma (HPV+OPC) is more sensitive to chemotherapy and radiotherapy, which translates to a much better prognosis with conventional treatment protocols than tumours that are HPV-negative. Traditional therapeutic interventions are associated with substantial morbidity and have a great impact on patient quality of life. The main focus is on identifying an ideal group of HPV-positive patients who could receive de-intensification treatment regimens aimed at avoiding the late toxicity of treatment. Various strategies are considered, such as reduction in radiotherapy dose following induction chemotherapy, radiotherapy alone, minimally invasive surgical techniques, and substituting platinum-based chemotherapy. The first generation of de-escalation randomised phase III trials have now been published. The following review summarizes the current knowledge and treatment of oropharyngeal carcinoma.

show abstract

Smoking during radiotherapy for head and neck cancer and acute mucosal reaction

Abstract: In the whole group, smoking during radiotherapy was not related to acute mucosal toxicity evaluated as the rate of the highest observed grade of mucositis.

Cited by 14 publications

References 24 publications

hTERT C250T promoter mutation and telomere length as a molecular markers of cancer progression in patients with head and neck cancer

hTERT C250T promoter mutation and telomere length as a molecular markers of cancer progression in patients with head and neck cancer

Smoking Prevalence and Management Among Cancer Survivors

Has the time come for de-escalation in the management of oropharyngeal carcinoma?

Contact Info

Product

Resources

About